Combination breast cancer chemotherapy with doxorubicin and cyclophosphamide damages bone and bone marrow in a female rat model
- 320 Downloads
Anthracyclines (including doxorubicin) are still the backbone of commonly used breast cancer chemotherapy regimens. Despite increasing use of doxorubicin and cyclophosphamide (AC) combinations for treating breast cancer, their potential to cause adverse skeletal effects remains unclear.
This study examined the effects of treatments with the AC regimen on bone and bone marrow in adult female rats.
AC treatment for four cycles (weekly intravenous injection of 2 mg/kg doxorubicin and 20 mg/kg cyclophosphamide) resulted in a reduced volume of trabecular bone at the metaphysis, which was associated with reduced serum levels of 25-hydroxy vitamin D3 and alkaline phosphatase. Reductions in densities of osteocytes and bone lining cells were also observed. In addition, bone marrow was severely damaged, including a severe reduction in bone marrow cellularity and an increase in marrow adipocyte content. Accompanying these changes, there were increases in mRNA expression of adipogenesis regulatory genes (PPARγ and FABP4) and an inflammatory cytokine (TNFα) in metaphysis bone and bone marrow.
This study indicates that AC chemotherapy may induce some bone loss, due to reduced bone formation, and bone marrow damage, due to increased marrow adiposity. Preventive strategies for preserving the bone and bone marrow microenvironment during anthracycline chemotherapy warrant further investigation.
KeywordsBreast cancer chemotherapy Bone loss Bone marrow adiposity Bone marrow damage Bone turnover Osteoclasts
This work was funded in parts by project grants from the Australian National Health Medical Research Council (NHMRC) (1010752) and Australian Research Council (LP120100519). Cory J. Xian is funded by NHMRC Senior Research Fellowship (1042105).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 8.Vehmanen L, Saarto T, Elomaa I, Makela P, Valimaki M, Blomqvist C (2001) Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment. Eur J Cancer 37(18):2373–2378CrossRefPubMedGoogle Scholar
- 10.Fan C, Georgiou KR, McKinnon RA, Keefe DM, Howe PR, Xian CJ (2016) Combination chemotherapy with cyclophosphamide, epirubicin and 5-fluorouracil causes trabecular bone loss, bone marrow cell depletion and marrow adiposity in female rats. J Bone Miner Metab 34(3):277–290. doi: 10.1007/s00774-015-0679-x CrossRefPubMedGoogle Scholar
- 18.Muss HB, Berry DA, Cirrincione C, Budman DR, Henderson IC, Citron ML, Norton L, Winer EP, Hudis CA (2007) Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. J Clin Oncol 25(24):3699–3704CrossRefPubMedGoogle Scholar
- 21.Moulin M, Piquereau J, Mateo P, Fortin D, Rucker-Martin C, Gressette M, Lefebvre F, Gresikova M, Solgadi A, Veksler V, Garnier A, Ventura-Clapier R (2015) Sexual dimorphism of doxorubicin-mediated cardiotoxicity: potential role of energy metabolism remodeling. Circ Heart Fail 8(1):98–108CrossRefPubMedGoogle Scholar
- 22.Sato M, Shiozawa K, Uesugi T, Hiromatsu R, Fukuda M, Kitaura K, Minami T, Matsumoto S (2009) Collaborative work on evaluation of ovarian toxicity. 7) Effects of 2- or 4- week repeated dose studies and fertility study of cyclophosphamide in female rats. J Toxicol Sci 34(Suppl 1):SP83–89PubMedGoogle Scholar
- 24.Raghu Nadhanan R, Skinner J, Chung R, Su YW, Howe PR, Xian CJ (2013) Supplementation with fish oil and genistein, individually or in combination, protects bone against the adverse effects of methotrexate chemotherapy in rats. PLoS ONE 8(8):e71592. doi: 10.1371/journal.pone.0071592 CrossRefPubMedPubMedCentralGoogle Scholar
- 34.Bowles EJ, Wellman R, Feigelson HS, Onitilo AA, Freedman AN, Delate T, Allen LA, Nekhlyudov L, Goddard KA, Davis RL, Habel LA, Yood MU, McCarty C, Magid DJ, Wagner EH, Pharmacovigilance Study T (2012) Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst 104(17):1293–1305CrossRefPubMedPubMedCentralGoogle Scholar
- 35.Edwards BJ, Raisch DW, Shankaran V, McKoy JM, Gradishar W, Bunta AD, Samaras AT, Boyle SN, Bennett CL, West DP, Guise TA (2011) Cancer therapy associated bone loss: implications for hip fractures in mid-life women with breast cancer. Clin Cancer Res 17(3):560–568CrossRefPubMedPubMedCentralGoogle Scholar
- 37.Michaud LB, Goodin S (2006) Cancer-treatment-induced bone loss, part 1. Am J Health 63(5):419–430Google Scholar
- 39.Chan HH, Chu TH, Chien HF, Sun CK, Wang EM, Pan HB, Kuo HM, Hu TH, Lai KH, Cheng JT, Tai MH (2010) Rapid induction of orthotopic hepatocellular carcinoma in immune-competent rats by non-invasive ultrasound-guided cells implantation. BMC Gastroenterol 10:83. doi: 10.1186/1471-230X-10-83 CrossRefPubMedPubMedCentralGoogle Scholar
- 40.Kim HJ, Koh BS, Yu JH, Lee JW, Son BH, Kim SB, Ahn SH (2014) Changes in serum hydroxyvitamin D levels of breast cancer patients during tamoxifen treatment or chemotherapy in premenopausal breast cancer patients. Eur J Cancer 50(8):1403–1411. doi: 10.1016/j.ejca.2014.02.026 CrossRefPubMedGoogle Scholar
- 48.Fujita K, Iwasaki M, Ochi H, Fukuda T, Ma C, Miyamoto T, Takitani K, Negishi-Koga T, Sunamura S, Kodama T, Takayanagi H, Tamai H, Kato S, Arai H, Shinomiya K, Itoh H, Okawa A, Takeda S (2012) Vitamin E decreases bone mass by stimulating osteoclast fusion. Nat Med 18(4):589–594. doi: 10.1038/nm.2659 CrossRefPubMedGoogle Scholar